Cargando…

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer

BACKGROUND: Several therapeutic agents are available for metastatic castration-resistant prostate cancer (CRPC). However, prognosis is still not well developed. The Gleason score (GS) is a prognostic factor available for patients with metastatic CRPC. GSs ranging from 6 to 10 and GSs ≥8 are usually...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishimoto, Mitsuhisa, Fujita, Kazutoshi, Yamamoto, Yutaka, Hashimoto, Mamoru, Adomi, Shogo, Banno, Eri, Saito, Yoshitaka, Shimizu, Nobutaka, Mori, Yasunori, Minami, Takafumi, Nozawa, Masahiro, Nose, Kazuhiro, Hirayama, Akihide, Yoshimura, Kazuhiro, Uemura, Hirotsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459578/ https://www.ncbi.nlm.nih.gov/pubmed/36093511 http://dx.doi.org/10.21037/tcr-22-375

Ejemplares similares

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients
por: Hashimoto, Mamoru, et al.
Publicado: (2021)

Sarcopenia and Visceral Obesity are Significantly Related to Severe Storage Symptoms in Geriatric Female Patients
por: Hashimoto, Mamoru, et al.
Publicado: (2021)

Reactivation of latent tuberculosis infection induced by cabazitaxel in a patient with prostate cancer: A case report
por: Hashimoto, Mamoru, et al.
Publicado: (2019)

Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a narrative review
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

A case of neuroendocrine tumor at the external urethral meatus after total cystectomy
por: Miki, Koji, et al.
Publicado: (2023)

Acotiamide hydrochloride hydrate added to combination treatment with an α-blocker and a cholinergic drug improved the QOL of women with acute urinary retention: case series
por: Sugimoto, Koichi, et al.
Publicado: (2017)

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis
por: Matsumura, Naoki, et al.
Publicado: (2021)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Survey on lower urinary tract symptoms and sleep disorders in patients treated at urology departments
por: Shimizu, Nobutaka, et al.
Publicado: (2013)

Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms
por: Shimizu, Nobutaka, et al.
Publicado: (2013)

The gut microbiota associated with high‐Gleason prostate cancer
por: Matsushita, Makoto, et al.
Publicado: (2021)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2022)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2015)

Procalcitonin as a useful marker to decide upon intervention for urinary tract infection
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system
por: Harashima, Nanae, et al.
Publicado: (2014)

Clinical Outcome of Small Renal Cell Carcinoma after Delayed Surgery versus Immediate Surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Comparison of the Safety and Efficacy of Photoselective Vaporization of the Prostate (PVP) and Transurethral Enucleation with a Bipolar System (TUEB): A Single-Center Retrospective Study
por: Kiba, Keisuke, et al.
Publicado: (2020)

Firmicutes in Gut Microbiota Correlate with Blood Testosterone Levels in Elderly Men
por: Matsushita, Makoto, et al.
Publicado: (2022)

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2020)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach
por: Nagao, Kazuhiro, et al.
Publicado: (2016)

Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model
por: Taguchi, Satoru, et al.
Publicado: (2020)

Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2017)

Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
por: Yoshimura, K, et al.
Publicado: (2013)

Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer
por: Hayashi, Takuji, et al.
Publicado: (2016)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome
por: Fujita, Kazutoshi, et al.
Publicado: (2023)

Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2016)

Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review
por: Chen, Wen-Jun, et al.
Publicado: (2020)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2013)

Lectures on Gleason parts
por: Bear, Herbert S
Publicado: (1970)

Dr. S. O. Gleason
Publicado: (1899)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade
por: Zelic, Renata, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kga3t3j58agp69vi3hgh6hfpjt